MBX Biosciences Business Summary

MBX Biosciences, Inc. (MBX) is a clinical-stage biopharmaceutical company that operates on a research-and-development business model, generating capital through public equity offerings and strategic collaborations rather than product sales. The company’s primary business segments are centered on its proprietary Precision Endocrine Peptide (PEP™) platform, which engineers long-acting, chemically optimized peptide prodrugs for endocrine and metabolic disorders. Its clinical pipeline is led by canvuparatide (MBX 2109) for chronic hypoparathyroidism, currently transitioning into Phase 3 trials, and imapextide (MBX 1416) for post-bariatric hypoglycemia. MBX is also aggressively expanding into the obesity market with MBX 4291, a long-acting GLP-1/GIP co-agonist designed for once-monthly dosing. Direct competitors include PTC Therapeutics, Kymera Therapeutics, and Protagonist Therapeutics; MBX distinguishes itself by leveraging its PEP™ technology to achieve superior pharmacokinetic profiles and reduced dosing frequency compared to traditional peptide therapies. MBX was co-founded by President and CEO Kent Hawryluk, a veteran life sciences entrepreneur who previously co-founded Avidity Biosciences and MB2, and Dr. Richard DiMarchi, a world-renowned peptide chemist and former Eli Lilly executive credited with inventing Humalog. The leadership team includes Chief Medical Officer Dr. Salomon Azoulay, formerly of Sumitovant Biopharma, and CFO Richard Bartram. The company’s strategic direction is further guided by Executive Chairperson Steven Hoerter and a board that recently added Laurie Stelzer (former CFO of Kailera Therapeutics) as Audit Chair in January 2026. MBX is backed by a high-pedigree investor base including Frazier Healthcare Partners, New Enterprise Associates (NEA), Norwest Venture Partners, and OrbiMed, providing a robust financial runway projected to fund operations into 2029.